United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - sirolimus - oral solution - 1mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - sirolimus - tablet - 1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - sirolimus - tablet - 2mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - sirolimus - tablet - 500microgram

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - coated tablets - sirolimus 1 mg - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - coated tablets - sirolimus 1 mg - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - solution (oral) - sirolimus 1 mg/ml - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose monohydrate, quantity: 50 g/l; dextran 70, quantity: 60 g/l - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - dextran 40, quantity: 100 g/l; sodium chloride, quantity: 9 g/l - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - dextran 40, quantity: 100 g/l; glucose monohydrate, quantity: 50 g/l - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)